Bli medlem
Bli medlem

Du är här

2015-12-16

Nordic Nanovector: NORDIC NANOVECTOR ASA - FINANCIAL CALENDAR

Date: 16.12.2015        Press Release no: 56/2015

Oslo, Norway, 16 December 2015

FINANCIAL YEAR 2015
Quarterly Report - Q4 - 26.02.2016

FINANCIAL YEAR 2016
Quarterly Report - Q1 - 19.05.2016
Quarterly Report - Q2 - 24.08.2016
Quarterly Report - Q3 - 16.11.2016

The dates are subject to change. The time and location of the
presentations will be announced in due time.

###

For further information, please contact:

Luigi Costa, Chief Executive Officer
Cell: +41 79 124 8601

Tone Kvåle, Chief Financial Officer
Tel: +47 22 18 33 01
Cell: +47 91 51 95 76

Email: tkvale@nordicnanovector.com

International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
nordicnanovector@citigatedr.co.uk
Tel: +44 207 282 2948/+44 207 282 2949

About Nordic Nanovector
Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and
oncology. The Company's lead clinical-stage product opportunity is
Betalutin®, the first in a new class of
Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and
complement current options for the treatment of non-Hodgkin Lymphoma
(NHL). NHL is an indication with substantial unmet medical need and
orphan drug opportunities, representing a growing market worth over
$12 billion by 2018.

Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1)
conjugated to a low intensity radionuclide (lutetium-177). The
preliminary data has shown promising efficacy and safety profile in
an ongoing Phase 1/2 study in a difficult-to-treat NHL patient
population. The Company is aiming at developing Betalutin® for the
treatment of major types of NHL with first regulatory submission
anticipated in 1H 2019.

Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets,
while exploring potential distribution agreements in selected
geographies. The Company is committed to developing its ARC pipeline
to treat multiple selected cancer indications.

Further information about the Company can be found at
www.nordicnanovector.com

-----------------------------------------------------------
http://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa---finan...

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.